Pharmaceuticals APAC News & Press Release Distribution

Pharmaceuticals

All
Global

Extended Malaysian wound care tender: Bactiguard Holding

STOCKHOLM, Aug. 25, 2021 /PRNewswire/ -- Bactiguard's tender award for wound care products for the public sector inMalaysia has been extended by another year and the volume has increased. This enables healthcare providers in both primary and secondary care to purchase Bactiguard's Wound Care syst...

2021-08-25 15:49 1335

Brii Biosciences Announces Positive Data from the Phase 3 ACTIV-2 Trial Evaluating Combination BRII-196 and BRII-198 in Non-Hospitalized COVID-19 Patients

DURHAM, N.C. and BEIJING, Aug. 25, 2021 /PRNewswire/ -- Brii Biosciences Limited ("Brii Bio" or the "Company", stock code: 2137.HK) a multi-national company developing innovative therapies for diseases with significant unmet medical need and large public health...

2021-08-25 08:42 2264

Ascletis Announces Completion of the Bridging Study and Initiation of Phase II Trial of FXR Agonist ASC42 in China for Chronic Hepatitis B Indication

HANGZHOU and SHAOXING, China, Aug. 25, 2021 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) announces today the completion of the bridging study and initiation of Phase II trial of farnesoid X receptor (FXR) agonist ASC42 inChina for chronic hepatitis B (CHB) indication. ASC42 is an in-house de...

2021-08-25 08:30 2176

Ascentage Pharma Announces 2021 Interim Results Highlighting the Potential of Its Core Drug Candidates and Major Breakthroughs in Strategic Collaborations

SUZHOU, China, and ROCKVILLE, Md., Aug. 24, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its 2021 interim results and released an updat...

2021-08-24 19:06 2706

Alphamab Oncology and CSPC Achieved an Licensing Cooperation on Anti-HER2 Bispecific Antibody KN026 in Mainland China

SUZHOU, China, Aug. 24, 2021 /PRNewswire/ -- Alphamab Oncology (stock code: 9966 HK) announced today that Jiangsu Alphamab Biopharmaceuticals Co., Ltd. ("Jiangsu Alphamab" or "the Company"), a wholly-owned subsidiary of Alphamab Oncology, signed a contract with JMT-Bio, a wholly-owned subsidiary ...

2021-08-24 15:08 2259

China Medical System Holdings Limited 2021 Interim Results Announcement

Business Performance Reached Record High Turnover Increased by 23.6% to RMB3,843.0 Million Profit Increased by 25.5% to RMB1,631.6 Million Industrial Investment Enables Innovation Incubation New Businesses Boost Future Development Financial Highlights For the 6 months ended 30 June 2021 (RMB ...

2021-08-24 10:52 3334

Genscript Biotech Reports 2021 Interim Financial Results

Strong Momentum across All Business Segments, particularly in Gene & Cell Therapy CDMO Continue to accelerate R&D investment to capture Future Growth * Revenue of the Group for the six months ended June 30, 2021 was approximately US$229.6 million, representing an increase of 38.0% as compared...

2021-08-24 01:32 3066

Himalaya Therapeutics Announces Registration of its Office in Shanghai

SHANGHAI and SAN DIEGO, Aug. 23, 2021 /PRNewswire/ -- Himalaya Therapeutics ("Himalaya"), a clinical-stage biopharmaceutical company focused on development and commercialization inGreater China, of a novel class of investigational antibody therapeutics for the treatment of solid tumor cancer, wh...

2021-08-23 22:10 1729

Study Confirms Viraleze Antiviral Nasal Spray Provides Protection Against SARS-CoV-2 in Challenge Model

MELBOURNE, Australia, Aug. 23, 2021 /PRNewswire/ -- Melbourne biotech company Starpharma has announced the publication of new data demonstrating the capability of its Viraleze antiviral nasal spray to protect against SARS-CoV-2 in an animal challenge model of SARS-CoV-2 infection[1]. Viraleze adm...

2021-08-23 20:23 3735

RedHill Biopharma Announces Two New U.S. Patents Covering Opaganib for Ebola Virus and RHB-104 for Crohn's

U.S. patents for opaganib combination for the treatment of Ebola virus disease provides patent protection until 2035 Opaganib's 475-patient global Phase 2/3 study in severe COVID-19 approaching completion with upcoming top-line results Opaganib also undergoing two oncology Phase 2 U.S. studies a...

2021-08-23 19:00 3715

Everest Medicines to Announce Half-Year 2021 Interim Results

SHANGHAI, Aug. 23, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inGreater China and other parts of Asia, today announced t...

2021-08-23 15:20 2936

Menarini Enters into an Exclusive Licensing Agreement with Daiichi Sankyo to Commercialise TARLIGE(R) in Singapore, Malaysia, and the Philippines

SINGAPORE, Aug. 23, 2021 /PRNewswire/ -- A. Menarini Asia-Pacific Holdings Pte. Ltd., part of the leading Italian global biopharmaceutical company Menarini Group, signed a multi-year exclusive licensing agreement to assume the registration, sales, marketing, and distribution of the orally adminis...

2021-08-23 09:00 1800

Inclusion of Kintor as a Constituent Stock of HSCI

SUZHOU, China, Aug. 23, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that the company's stock has been included in the Hang Seng Composite ...

2021-08-23 08:44 2533

Ocumension Therapeutics Announces 2021 Interim Results

Company loss narrowed sharply by 96% Business Income Increased By More Than 26 Times Year-on-Year Core Product OT-401 Approval Imminent HONG KONG, Aug. 21, 2021 /PRNewswire/ -- The Chinese ophthalmology platform company,Ocumension Therapeutics ("Ocumension" or the "Company", together with its s...

2021-08-21 00:19 16413

CStone Pharmaceuticals Selected as a Constituent of HSCI

SUZHOU, China, Aug. 20, 2021 /PRNewswire/ -- CStone Pharmaceuticals (HKEX: 2616, "CStone" or the "Company"), a leading biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology therapies and precision medicines, announced that the Company has bee...

2021-08-20 20:24 5244

Standigm Expands Global Footprints with New Office in Cambridge, UK

SEOUL, South Korea, Aug. 20, 2021 /PRNewswire/ -- Standigm, a leading workflow AI drug discovery company, today announced the opening of a new office in Cambridge, United Kingdom ("UK"), to accommodate the company's rapid growth in the European market. Founded in 2015, Standigm has proprietary ...

2021-08-20 15:30 1217

Zhaoke Ophthalmology's Phase III Clinical Trial of Cyclosporine A (CsA) Ophthalmic Gel for Dry Eye Disease Meets Primary Endpoint

Largest Ever Completed Dry Eye Disease (DED) clinical trial to date in China Zhaoke Ophthalmology's in-house developed innovative drug candidate Targeting NDA Filing by the End of 2021 Dry Eye Disease Affects Over 200 Million People in China Potential to become new standard of care for moderate-to-s...

2021-08-19 12:43 3029

MicroConstants to Join BioAgilytix Family

Highly complementary transaction strengthens BioAgilytix's ability to support bioanalytical services across all major therapeutics in development; adds LC/MS/MS capabilities; and expands team of seasoned scientists DURHAM, N.C., Aug. 19, 2021 /PRNewswire/ -- BioAgilytix Labs, LLC (BioAgilytix), ...

2021-08-19 02:30 1562

Seegene Q2 2021 Earnings Show 11 Percent Revenue Growth, YoY

- Revenue of KRW 303.7 billion ($269.1 million) is record for second quarter, up 11 percent year-over-year - 1H'21 Revenue at KRW 655.5 billion ($580.8 million), 58 percent achievement based on total sales in FY2020 - Favorable market conditions expected in second half amid an increasing dem...

2021-08-18 18:00 1451

Transcenta Held Investigator Meeting and Initiated Phase IIa Clinical Trial of Claudin18.2 Monoclonal Antibody TST001 with First Patient Dosed Successfully

SUZHOU, China, Aug. 18, 2021 /PRNewswire/ -- Transcenta announced that it held an investigator meeting successfully for TST001 Phase I clinical trial study on August 14. Professors Lin Shen and Jifang Gong from Beijing Cancer Hospital, ProfessorWeijian Guo from Fudan University Shanghai Cancer Cen...

2021-08-18 08:00 1942

1 ... 107 108 109110111 112 113 ... 181